Search details
1.
Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.
N Engl J Med
; 387(8): 715-726, 2022 08 25.
Article
in English
| MEDLINE | ID: mdl-36001712
2.
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
N Engl J Med
; 386(4): 316-326, 2022 01 27.
Article
in English
| MEDLINE | ID: mdl-35081280
3.
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
Ann Rheum Dis
; 82(9): 1130-1141, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37308218
4.
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
Ann Rheum Dis
; 82(12): 1516-1526, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37699654
5.
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).
Ann Rheum Dis
; 82(12): 1527-1537, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37696589
6.
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
Ann Rheum Dis
; 82(6): 773-787, 2023 06.
Article
in English
| MEDLINE | ID: mdl-35953263
7.
Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis.
Rheumatology (Oxford)
; 62(10): 3268-3279, 2023 10 03.
Article
in English
| MEDLINE | ID: mdl-36727470
8.
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.
Rheumatology (Oxford)
; 62(5): 1804-1813, 2023 05 02.
Article
in English
| MEDLINE | ID: mdl-36018230
9.
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study.
Ann Rheum Dis
; 81(12): 1661-1668, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36109142
10.
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study.
Rheumatology (Oxford)
; 61(6): 2413-2423, 2022 05 30.
Article
in English
| MEDLINE | ID: mdl-34498056
11.
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis.
Ann Rheum Dis
; 80(4): 432-439, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33148701
12.
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Ann Rheum Dis
; 80(1): 71-87, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33158881
13.
Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors.
Rheumatology (Oxford)
; 60(11): 4991-5001, 2021 11 03.
Article
in English
| MEDLINE | ID: mdl-33871596
14.
Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE.
Rheumatology (Oxford)
; 60(12): 5583-5594, 2021 12 01.
Article
in English
| MEDLINE | ID: mdl-33590829
15.
Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
Ann Rheum Dis
; 79(10): 1290-1297, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32788396
16.
Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
Rheumatology (Oxford)
; 59(10): 2774-2784, 2020 10 01.
Article
in English
| MEDLINE | ID: mdl-32031665
17.
Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up.
Rheumatology (Oxford)
; 59(2): 292-302, 2020 02 01.
Article
in English
| MEDLINE | ID: mdl-31312844
18.
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study.
Clin Exp Rheumatol
; 38(5): 848-857, 2020.
Article
in English
| MEDLINE | ID: mdl-31858963
19.
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Lancet
; 391(10139): 2513-2524, 2018 06 23.
Article
in English
| MEDLINE | ID: mdl-29908670
20.
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
Ann Rheum Dis
; 78(11): 1454-1462, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31362993